Sysmex (OTCMKTS:SSMXY) Updates FY 2024 Earnings Guidance

Sysmex (OTCMKTS:SSMXY) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 0.580-0.580 for the period. The company issued revenue guidance of $3.3 billion-$3.3 billion.

Sysmex Trading Down 0.8 %

Shares of Sysmex stock traded down $0.14 during trading hours on Friday, hitting $18.08. The company’s stock had a trading volume of 50,464 shares, compared to its average volume of 84,987. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.42 and a current ratio of 3.19. Sysmex has a twelve month low of $14.38 and a twelve month high of $28.58. The firm has a fifty day moving average of $18.80 and a 200-day moving average of $19.01. The stock has a market cap of $11.38 billion, a price-to-earnings ratio of 36.91 and a beta of 0.90.

Sysmex (OTCMKTS:SSMXY) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter. Research analysts forecast that Sysmex will post 0.57 EPS for the current year.

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.